Home
Our Science
Vision
Drug discovery process
Drug development process
A history of innovation
Disease Areas
Autoimmunity & Transplantation
Cardiovascular
Diabetes & Metabolism
Gastrointestinal
Ophthalmology
Infectious Diseases
Musculoskeletal
Neuroscience
Respiratory Diseases
Oncology
Expertise Platforms
NIBR Biologics Center
Developmental & Molecular Pathways
Center for Proteomic Chemistry
Epigenetics
Global Discovery Chemistry
Strategic Alliances
Why collaborate with us
The process
Current alliances
Contact us
Careers
Working at NIBR
Presidential Postdoc
Internships
People of NIBR
Elizabeth George
Fran Heller
Paolo Paganetti
Christopher Poll
Gabriele Weitz-Schmidt
About the Institutes
Worldwide locations
Senior management
Mark Fishman
Jeffrey Elton
Ginger Gregory
Christian Klee
Brigitta Tadmor
Scientific leaders
Graeme Bilbe
Scott Biller
Sylvain Cottens
Jan de Vries
Tom Evans
Alyson Fox
John Hastewell
Thomas Hughes
Seigo Izumo
Mark Keating
En Li
Jeff Porter
Brian Richardson
William Sellers
John Westwick
News, Events & Publications
News archive
Events
NIBR publications
Our challenge is to acquire, support and retain the best of talents.
We intend to forge the new science of drug discovery and are committed to deliver new medicines effectively, reliably and predictably.
Learn more about the scientific milestones at Novartis and its ancestor companies.